{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:07:16Z","timestamp":1784592436420,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T00:00:00Z","timestamp":1357603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Adverse drug reactions (ADRs) are recognised as a common cause of hospital admissions, and they constitute a significant economic burden for hospitals. Hospital-based ADR monitoring and reporting programmes aim to identify and quantify the risks associated with the use of drugs provided in a hospital setting. This information may be useful for identifying and minimising preventable ADRs and may enhance the ability of prescribers to manage ADRs more effectively. The main objectives of this study were to evaluate ADRs that occurred during inpatient stays at the Hospital Geral de Palmas (HGP) in Tocantins, Brazil, and to facilitate the development of a pharmacovigilance service.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A prospective study was conducted at HGP over a period of 8 months, from January 2009 to August 2009. This observational, cross-sectional, descriptive study was based on an analysis of medical records. Several parameters were utilised in the data evaluation, including patient demographics, drug and reaction characteristics, and reaction outcomes. The reaction severity and predisposing factors were also assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The overall incidence of ADRs in the patient population was 3.1%, and gender was not found to be a risk factor. The highest ADR rate (75.8%) was found in the adult age group 15 to 50 years, and the lowest ADR rate was found in children aged 3 to 13 years (7.4%). Because of the high frequency of ADRs in orthopaedic (25%), general medicine (22%), and oncology (16%) patients, improved control of the drugs used in these specialties is required. Additionally, the nurse team (52.7%) registered the most ADRs in medical records, most likely due to the job responsibilities of nurses. As expected, the most noticeable ADRs occurred in skin tissues, with such ADRs are more obvious to medical staff, with rashes being the most common reactions. Metamizole, tramadol, and vancomycin were responsible for 21, 11.6, and 8.4% of ADRs, respectively. The majority of ADRs had moderate severity (58.9%), thus requiring intervention. Type A reactions were the most common (82.1%). At least one predisposing factor was present in 79.9% of the reports examined, and the most common predisposing factor was polypharmacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The results obtained will contribute to the development of strategies for the pharmacovigilance service at HGP and other hospitals throughout the country, which will improve the quality of ADR reporting and ensure safer drug use in Brazilian hospitals.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/2050-6511-14-5","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T04:36:46Z","timestamp":1357706206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil"],"prefix":"10.1186","volume":"14","author":[{"given":"M\u00e1rcia Germana Alves de Ara\u00fajo","family":"Lobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Maria Botelho","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Gerley D\u00edaz","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ria Gomes","family":"Moment\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Cristina S","family":"Pranchevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,8]]},"reference":[{"key":"112_CR1","first-page":"1","volume-title":"Technical report series no. 425","author":"World Health Organization","year":"1966","unstructured":"World Health Organization: International drug monitoring: the role of the hospital. Technical report series no. 425. 1966, Geneva, Switzerland: World Health Organization, 1-24."},{"key":"112_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00228-002-0501-2","volume":"58","author":"L Juntti-Patinen","year":"2002","unstructured":"Juntti-Patinen L, Neuvoren PJ: Drug-related deaths in a university central hospital. Eur J Clin Pharmacol. 2002, 58: 479-482. 10.1007\/s00228-002-0501-2.","journal-title":"Eur J Clin Pharmacol"},{"key":"112_CR3","first-page":"125","volume-title":"Ci\u00eancias Farmac\u00eauticas. Uma Abordagem em Farm\u00e1cia Hospitalar","author":"SMS Magalh\u00e3es","year":"2001","unstructured":"Magalh\u00e3es SMS, Carvalho WS: Rea\u00e7\u00f5es Adversas a Medicamentos. Ci\u00eancias Farmac\u00eauticas. Uma Abordagem em Farm\u00e1cia Hospitalar. 2001, S\u00e3o Paulo: Atheneu, 125-146."},{"key":"112_CR4","volume-title":"Rea\u00e7\u00f5es adversas a medicamentos em uma popula\u00e7\u00e3o idosa hospitalizada. PhD thesis","author":"MCG Passarelli","year":"2005","unstructured":"Passarelli MCG: Rea\u00e7\u00f5es adversas a medicamentos em uma popula\u00e7\u00e3o idosa hospitalizada. PhD thesis. 2005, Universidade de S\u00e3o Paulo, Faculdade de Medicina"},{"key":"112_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2165\/00003088-199733050-00002","volume":"33","author":"R Lobstein","year":"1997","unstructured":"Lobstein R, Lakin A, Koren G: Pharmacokinetic Changes during pregnancy and Their clinical Relevance. Clinical Pharmacokinet. 1997, 33: 328-343. 10.2165\/00003088-199733050-00002.","journal-title":"Clinical Pharmacokinet"},{"key":"112_CR6","first-page":"379","volume":"79","author":"A Wong","year":"2003","unstructured":"Wong A: Os usos inadequados e os efeitos adversos de medicamentos na pr\u00e1tica cl\u00ednica. J Pediatr (Rio J). 2003, 79: 379-380.","journal-title":"J Pediatr (Rio J)"},{"key":"112_CR7","volume-title":"Textbook of therapeutics, drug and disease management","author":"DS Tatro","year":"1996","unstructured":"Tatro DS: Textbook of therapeutics, drug and disease management. 1996, Baltimore: William and Wilkins"},{"key":"112_CR8","first-page":"101","volume-title":"Adverse drug reactions and interactions","author":"RJ May","year":"1997","unstructured":"May RJ: Pharmacoterapy: a pathophysiologic approach. Adverse drug reactions and interactions. 1997, Norwalk: Appleton & Lange, 101-116."},{"key":"112_CR9","unstructured":"Laporte JR: Famacovigil\u00e2ncia Hospitalar.http:\/\/www.cvs.saude.sp.gov.br\/farde_hos.html,"},{"key":"112_CR10","first-page":"36","volume":"22","author":"A Brand\u00e3o","year":"2000","unstructured":"Brand\u00e3o A, Vasconcelos F: A t\u00eanue fronteira entre a cura e o malef\u00edcio. Pharmacia Brasileira. 2000, 22: 36-39.","journal-title":"Pharmacia Brasileira"},{"key":"112_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1177\/106002809302700206","volume":"27","author":"TR Einarson","year":"1993","unstructured":"Einarson TR: Drug-related hospital admissions. Ann Pharmacother. 1993, 27: 832-840.","journal-title":"Ann Pharmacother"},{"key":"112_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998, 279: 1200-1205. 10.1001\/jama.279.15.1200.","journal-title":"JAMA"},{"key":"112_CR13","volume-title":"Declara\u00e7\u00e3o de Berlim sobre Farmacovigil\u00e2ncia","author":"Sobravime","year":"2005","unstructured":"Sobravime: Declara\u00e7\u00e3o de Berlim sobre Farmacovigil\u00e2ncia. 2005, S\u00e3o Paulo"},{"key":"112_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/pds.897","volume":"3","author":"K Van Grootheest","year":"2004","unstructured":"Van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L: Pharmacists\u2019 role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004, 3: 457-464.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 6","key":"112_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1043-6618(03)00003-3","volume":"47","author":"L Gallelli","year":"2003","unstructured":"Gallelli L, Ferreri G, Colosimo M, Pirritano D, Flocco MA, Pelaia G: Retrospective analysis of adverse drug reactions to bronchodilatorsobserved in two pulmonary divisions of Catanzaro, Italy. Pharmacol Res. 2003, 47 (Suppl 6): 493-499.","journal-title":"Pharmacol Res"},{"issue":"Suppl 3","key":"112_CR16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ajhp\/60.3.253","volume":"60","author":"WK Wu","year":"2003","unstructured":"Wu WK: Evaluation of outpatient adverse drug reactions leading to hospitalization. Am J Health Syst Pharm. 2003, 60 (Suppl 3): 253-259.","journal-title":"Am J Health Syst Pharm"},{"key":"112_CR17","first-page":"18","volume-title":"Textbook of adverse drug reactions","author":"MD Rawlins","year":"1981","unstructured":"Rawlins MD, Thompson JW: Mechanisms of adverse drug reactions. Textbook of adverse drug reactions. 1981, Oxford: Oxford University press, 18-45. 4","edition":"4"},{"key":"112_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"2","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Robert EA, Ecek E, Domeck C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clinic Pharmacological Therapeutic. 1981, 2: 239-245.","journal-title":"Clinic Pharmacological Therapeutic"},{"key":"112_CR19","first-page":"2268","volume":"51","author":"TF Pearson","year":"1994","unstructured":"Pearson TF, Pittman D, Longley JM, Grapes T, Vigliotti DJ, Mullis SR: Factors associated with preventable adverse drug reactions. Am J Hosp Pharm. 1994, 51: 2268-2271.","journal-title":"Am J Hosp Pharm"},{"key":"112_CR20","volume-title":"Interven\u00e7\u00e3o farmac\u00eautica na qualidade assistencial e nas rea\u00e7\u00f5es adversas de amitriptilina prescrita para pacientes ambulatoriais do Sistema \u00danico de Sa\u00fade de Ribeir\u00e3o Preto. PhD thesis","author":"Sebasti\u00e3o ECO","year":"2005","unstructured":"Sebasti\u00e3o ECO: Interven\u00e7\u00e3o farmac\u00eautica na qualidade assistencial e nas rea\u00e7\u00f5es adversas de amitriptilina prescrita para pacientes ambulatoriais do Sistema \u00danico de Sa\u00fade de Ribeir\u00e3o Preto. PhD thesis. 2005, Universidade de S\u00e3o Paulo, Faculdade de Ci\u00eancias Farmac\u00eauticas"},{"key":"112_CR21","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: Completed ATC Index. 2005, [http:\/\/www.whocc.no\/atcddd\/]"},{"key":"112_CR22","volume-title":"O custo das rea\u00e7\u00f5es adversas medicamentosas em hospitais","author":"MAP Puerro","year":"2004","unstructured":"Puerro MAP: MSc thesis. O custo das rea\u00e7\u00f5es adversas medicamentosas em hospitais. 2004, Universidade de S\u00e3o Paulo, Faculdade de Sa\u00fade P\u00fablica"},{"key":"112_CR23","unstructured":"Merck Sharp Dohme: Aspectos gerais dos medicamentos. Manual Merck. Sa\u00fade para a fam\u00edlia. Se\u00e7\u00e3o 2 \u2013 Medicamentos. Cap\u00edtulo 5, [http:\/\/mmspf.msdonline.com.br\/pacientes\/manual_merck\/secao_02\/cap_005.html]"},{"key":"112_CR24","unstructured":"Harnik S: Respostas nocivas a medicamentos podem ser evitadas, diminuindo custos. [http:\/\/www.usp.br\/agen\/bols\/2004\/rede1426.htm]"},{"key":"112_CR25","volume-title":"Ci\u00eancias Farmac\u00eauticas: Uma Abordagem em Farm\u00e1cia Hospitalar","author":"MJV Gomes","year":"2001","unstructured":"Gomes MJV, Reis AAMM: Ci\u00eancias Farmac\u00eauticas: Uma Abordagem em Farm\u00e1cia Hospitalar. 2001, S\u00e3o Paulo: Atheneu"},{"key":"112_CR26","first-page":"1","volume":"41","author":"S Rozenfeld","year":"2006","unstructured":"Rozenfeld S: Agravos provocados por medicamentos em hospitais do Estado do Rio de Janeiro. Rev Saude Publica. 2006, 41: 1-8.","journal-title":"Rev Saude Publica"},{"key":"112_CR27","volume-title":"Incid\u00eancia de rea\u00e7\u00f5es adversas a medicamentos em Hospital de Ensino do Nordeste do Brasil. MSc thesis","author":"AP Gomes","year":"2004","unstructured":"Gomes AP: Incid\u00eancia de rea\u00e7\u00f5es adversas a medicamentos em Hospital de Ensino do Nordeste do Brasil. MSc thesis. 2004, Universidade Federal do Cear\u00e1, Faculdade de Ci\u00eancias Farmac\u00eauticas"},{"key":"112_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1590\/S0104-42302002000300037","volume":"48","author":"G Pfaffenbach","year":"2002","unstructured":"Pfaffenbach G, Carvalho OM, Bergsten-Mendes G: Rea\u00e7\u00f5es adversas a medicamentos como determinantes da admiss\u00e3o hospitalar. Rev Assoc Med Bras. 2002, 48: 237-241. 10.1590\/S0104-42302002000300037.","journal-title":"Rev Assoc Med Bras"},{"key":"112_CR29","first-page":"96","volume-title":"Farmacoterapia Pedi\u00e1trica","author":"DA Notteerman","year":"1993","unstructured":"Notteerman DA: Farmacologia em Terapia Intensiva. Farmacoterapia Pedi\u00e1trica. 1993, Rio de Janeiro: Revinter, 96-120."},{"key":"112_CR30","first-page":"23","volume":"41","author":"EO Louro","year":"2004","unstructured":"Louro EO: Perfil de utiliza\u00e7\u00e3o de medicamentos e monitora\u00e7\u00e3o de rea\u00e7\u00f5es adversas em pacientes pedi\u00e1tricos no Hospital Albert Sabin em S\u00e3o Paulo. Rev Saude Publica. 2004, 41: 23-29.","journal-title":"Rev Saude Publica"},{"key":"112_CR31","volume-title":"Avalia\u00e7\u00e3o do sistema de farmacovigil\u00e2ncia do instituto de doen\u00e7as tropicais Natan Portella em Teresina \u2013 PI. MSc Thesis","author":"FPM Amaral","year":"2006","unstructured":"Amaral FPM: Avalia\u00e7\u00e3o do sistema de farmacovigil\u00e2ncia do instituto de doen\u00e7as tropicais Natan Portella em Teresina \u2013 PI. MSc Thesis. 2006, Universidade Federal do Cear\u00e1, Faculdade de Medicina"},{"key":"112_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","volume":"274","author":"DW Bates","year":"1995","unstructured":"Bates DW, Cullen DJ, Laird N: Incidence of adverse drug events and potential adverse drug events. JAMA. 1995, 274: 29-34. 10.1001\/jama.1995.03530010043033.","journal-title":"JAMA"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2050-6511-14-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:52:46Z","timestamp":1630533166000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/2050-6511-14-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1186\/2050-6511-14-5","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,8]]},"assertion":[{"value":"17 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"5"}}